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PURPOSE. Retinitis pigmentosa (RP) refers to a group of inherited blinding retinal diseases,
whereby the death of mutated rod photoreceptors is followed closely by the death of cone
photoreceptors. Cone cell death can be hugely debilitating as color/daytime vision becomes
impaired. Thus, treatments that are effective against cone cell death are urgently needed. Our
research has been working toward development of a neuroprotective treatment for RP. We
have previously demonstrated significant neuroprotective properties of norgestrel, a
progesterone analogue, in the mouse retina. The current study further investigates the
potential of norgestrel as a treatment for RP, with a focus on long-term preservation of cone
photoreceptors.
METHODS. Using the well-established rd10 mouse model of RP, we administered a norgestrel-
supplemented diet at postnatal day (P)30, following widespread loss of rod photoreceptors
and at the outset of cone degeneration. We subsequently assessed cone cell morphology and
retinal function at P50, P60, and P80, using immunohistochemistry, electroretinograph
recordings, and optomotor testing.
RESULTS. While cone cell degeneration was widespread in the untreated rd10 retina, we
observed profound preservation of cone photoreceptor morphology in the norgestrel-treated
mice for at least 50 days, out to P80. This was demonstrated by up to 28-fold more cone
arrestin-positive photoreceptors. This protection transpired to functional preservation at all
ages.
CONCLUSIONS. This work presents norgestrel as an incredibly promising long-term neuropro-
tective compound for the treatment of RP. Crucially, norgestrel could be used in the mid-late
stages of the disease to protect remaining cone cells and help preserve color/daytime vision.
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Retinitis pigmentosa (RP) is the most prevalent inheritedretinal disease, affecting 2 million people worldwide.
Mutations in over 60 genes have been implicated in RP that
are expressed almost exclusively in rod photoreceptors,1,2 and
ultimately result in rod cell demise and reduced vision in low
light (nyctalopia). During this stage, vision in bright light is
largely unaffected as cone cells continue to function. Although
rarely mutated, cone cells die as a consequence of the death of
neighboring rod photoreceptors. This has detrimental effects
on vision in daylight (achromatopsia). Hence, therapeutic
approaches that promote cone cell survival in RP would be
life-changing for those affected. It is vital that such therapeutic
interventions be effective when administered during or
following rod cell death, as rod cell death can go unnoticed
for some time and accounts for up to 95% photoreceptor loss.3
Rods are a vital source of trophic support for cones
throughout life.4 Loss of trophic support from rods precedes
an exposure to toxic reactive oxygen species (ROS), generated
from the death of rods.5,6 Hence, oxidative stress is a major
contributory factor in the death of cone cells.7 Starvation of
nutrients, leading to a dysregulation of cellular metabolism, was
demonstrated to drive cone cell death in RP.8 As cone cells die,
they release chemoattractants that mobilize and attract
inflammatory cells, which can potentiate cone cell death.9–11
Therefore, a loss of trophic support, nutrient deprivation,
oxidative stress, and inflammation are all implicated in cone
cell death in RP.
The widely studied rd10 mouse model harbors a point
mutation in pde6b, which encodes for phosphodiesterase 6b,12
an essential component of the rod phototransduction cascade.
Mutations in pde6b are found in nonsyndromic cases of RP.2,13
Retinal degeneration in the rd10 retina transpires as an initial,
rapid loss of rod photoreceptors in the first 3 postnatal weeks,
followed closely by a slower degeneration of cone cells into
adulthood.14–16
Studies have shown that cone cell survival can be prolonged
in animal models of retinal disease by combating processes
such as trophic factor loss, nutrient deprivation, inflammation,
and oxidative stress.5,8,17–23 In 2011, we revealed the neuro-
protective properties of norgestrel, a synthetic progestin
(progesterone analogue), in the rd10 mouse24 and since then
in several models of retinal degeneration.25–28 These studies
involved administration of norgestrel prior to photoreceptor
cell death and assessment of degeneration in the early stages. As
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mentioned earlier, therapeutic approaches that are effective in
the later stages of the disease are needed. In the current study,
we investigated the efficacy of norgestrel in protecting cone
cells over long periods and in an already degenerating retina.
This is essential to study, as cone and rod cell death differ
greatly in terms of the rate and underlying cellular and
molecular processes.7,29,30 Therefore, we cannot assume that
norgestrel’s neuroprotective capacity is independent of the
degenerative stage of the retina and the photoreceptor cell
type undergoing cell death. We administered a norgestrel-
supplemented diet to rd10 mice at postnatal day (P)30, when
rod cell death is almost complete and cone cell degeneration is
beginning. We subsequently assessed cone cell survival and
function at P50, P60, and P80.
MATERIALS AND METHODS
Mice
All animals were handled and maintained following the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research (License AE19130). Experiments were approved by
University College Cork Animal Experimentation Ethics Com-
mittee and were performed using both male and female
C57BL/6 and homozygous rd10/rd10 mice (B6.CXBI-
Pde6brd10/J). Mice were supplied by the Biological Services
Unit, University College Cork and were humanely euthanized
by cervical dislocation. Mice were exposed to a 12-hour
light:12-hour dark cycle.
Norgestrel-Supplemented Diet
Norgestrel-supplemented and control diets were manufactured
by TestDiet (St. Louis, MO, USA). Norgestrel was added to the
chow at a concentration of 0.05% (500 ppm). Rd10 mice were
given a norgestrel-supplemented diet (TestDiet; LabDiet
9GWW, custom diet containing D() norgestrel; norgestrel
purchased from Sigma-Aldrich Corp., St. Louis, MO, USA) from
P30. This equates to a daily intake of approximately 80 mg/kg,
assuming a 30-g mouse consumes around 5 g food/day. With
untreated litters, diet changes were replicated with a control
diet (LabDiet 5053 control diet).
Immunofluorescence
Whole eyes/retinal whole mounts were fixed at room
temperature in 4% paraformaldehyde (PFA) for 1.5 hours and
30 minutes, respectively. Following washes, eyes were
cryoprotected in 15% sucrose in 13 PBS for 1 hour, 20%
sucrose for 1 hour, and 30% sucrose overnight, all at 48C. Eyes
were submerged and frozen in cryochrome (Thermo Fisher
Scientific) and sectioned on a cryostat (Leica, Wetzlar,
Germany). Sections (7 or 20 lm) were collected on Superfrost
glass slides (Thermo Fisher Scientific) and stored at 808C.
Sections were blocked and permeabilized with 0.1% Triton X-
100 and 5% donkey serum in 13 PBS for 30 minutes and
incubated with primary antibody diluted in 5% donkey serum
overnight at 48C. Retinal whole mounts were blocked and
permeabilized with 4% Triton X-100 and 5% donkey serum in
13 PBS for 1.5 hours and incubated with primary antibody
overnight at 48C. The Table lists the details of all primary
TABLE. List of Antibodies Used for Immunofluorescence and Western Blotting
Antibody Supplier Catalogue No. Host Dilution
Cone arrestin Merck Millipore AB15282 Rabbit polyclonal IF 1:100
Rhodopsin Thermo Fisher Scientific MS-1233 Mouse monoclonal IF 1:100
Synaptophysin Merck Millipore MAB5258 Mouse monoclonal IF 1:500
Iba1 Wako 019-19741 Rabbit polyclonal IF 1:500
CD68 AbD Serotec MCA1957 Rat monoclonal IF 1:500
GFAP Dako Z0334 Rabbit monoclonal IF 1:500
WB 1:1000
Glutamine synthetase Merck Millipore MAB302 Mouse monoclonal IF 1:100
WB 1:1000
Acrolein Abcam Ab37110 Rabbit polyclonal IF 1:500
SOD1 Abcam Ab13498 Rabbit polyclonal WB 0.2 lg/mL
SOD2 Abcam Ab13533 Rabbit polyclonal WB 1:5000
Catalase Cell Signaling 14097 Rabbit monoclonal WB 1:1000
Glutathione reductase Abcam Ab16801 Rabbit polyclonal WB 1:2000
Glutathione Peroxidase Abcam Ab22604 Rabbit polyclonal WB 1 lg/mL
Bcl-2 Cell Signaling 2870 Rabbit monoclonal WB 1:1000
Bax Cell Signaling 2772 Rabbit polyclonal WB 1:1000
Caspase 3 Cell Signaling 9662 Rabbit polyclonal WB 1:1000
Caspase 9 Cell Signaling 9508 Mouse monoclonal WB 1:1000
pAkt Cell Signaling 9271 Rabbit polyclonal WB 1:1000
Akt Cell Signaling 9272 Rabbit polyclonal WB 1:1000
mTOR Cell Signaling 5536 Rabbit monoclonal WB 1:1000
TOR Cell Signaling 2983 Rabbit monoclonal WB 1:1000
pERK1/2 Cell Signaling 9106 Mouse monoclonal IF 1:500
WB 1:2000
pERK1/2 Cell Signaling 4376 Rabbit monoclonal IF 1:500
ERK1/2 Cell Signaling 9102 Rabbit polyclonal WB 1:1000
pMEK1/2 Cell Signaling 9154 Rabbit monoclonal WB 1:1000
MEK1/2 Cell Signaling 8727 Rabbit monoclonal WB 1:1000
Supplier locations: Merck Millipore (Burlington, MA, USA); Wako (Richmond, VA, USA); AbD Serotec (Hercules, CA, USA), Dako (Santa Clara, CA, USA),
Abcam (Cambridge, UK), Cell Signaling (Danvers, MA, USA), Thermo Fisher Scientific (Waltham, MA, USA). IF, immunofluorescence; WB, Western blotting.
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antibodies used. Following washes, sections/retinal whole
mounts were incubated with secondary antibody (Alexa Fluor
donkey anti-mouse/rabbit/goat with either a 488 or a 594
fluorescent probe; Molecular Probes, Eugene, OR, USA) and
Hoechst 33342 nuclear stain (1:10,000; Thermo Fisher
Scientific) for 1 and 2 hours, respectively, at room temperature.
Eliminating the primary antibody in solution served as a
negative control. Sections/retinal whole mounts were mounted
using Mowiol (Sigma-Aldrich Corp.) with Dabco antifade agent
(Sigma-Aldrich Corp.).
Western Blotting
Whole retinas were homogenized in RIPA buffer (Thermo
Fisher Scientific) containing protease and phosphatase inhib-
itors (Thermo Fisher Scientific). Tissue lysates were centri-
fuged at 48C at 15,294g for 30 minutes. Supernatant was stored
at808C. Protein concentration was measured using a Bradford
assay (Bio-Rad, Hercules, CA, USA). Next, 4% to 15% gradient
gels (Bio-Rad) were used for SDS-PAGE and proteins were then
transferred to a nitrocellulose membrane. Protein (20–30 lg)
was loaded per sample. Total protein levels are an accurate
way of verifying equal loading31 and so were analyzed using
REVERT Total Protein Stain (LiCor, Lincoln, NE, USA) per
manufacturer’s instructions and imaged on a LiCor scanner in
the 700 channel. Membranes were blocked using Odyssey
blocking buffer (LiCor) for 30 minutes and probed with
primary antibody overnight at 48C. The Table lists details of the
primary antibodies used. Densitometry analysis for proteins of
interest was normalized to total protein. Membranes were
washed using 13 tris-buffered saline with 1% tween-20 (TBS-T)
and probed with IRDye 800CW and 680RD secondary
antibodies (LiCor). Membranes were imaged on a LiCor
scanner. Densitometry analysis was performed using Image
Studio Lite (LiCor).
Microscopy and Quantification
Retinal sections and cell preparations were viewed using a
Leica DM LB2 microscope with Nikon Digital Sight DS-U2
camera (Kanagawa, Japan), using 310 and 340 objectives.
Images were taken using the software NIS-Elements version 3.0
(Nikon). Confocal micrographs were taken using an Olympus
Fluoview FV1000 laser scanning confocal microscope (Shinju-
ku, Tokyo, Japan), using320 and340 objectives. Images were
taken using the software Olympus Fluoview Ver 4.1a and are
represented as maximum-intensity projections from acquisi-
tion of z-stacks, inclusive of all retinal layers. All images shown
were taken in the central retina. Fluorescence intensity
measurements were taken using ImageJ software (National
Institutes of Health, Bethesda, MD, USA). Samples were
processed at the same time using the same buffers and
antibody solutions. Identical microscope settings were used
when imaging each preparation across treatment groups, and
images were taken in the same session. Numbers of cone
arrestin-positive photoreceptors from whole-mount retinas
were counted from acquired 340 images. Numbers of
microglia/macrophages from whole-mount retinas included
Iba1þ cells with a distinct cell body.
Phosphoreceptor Tyrosine Kinase Assay
A mouse phospho-RTK array kit was purchased from R&D
systems (ARY014; Minneapolis, MN, USA). This kit contains
membranes with embedded antibodies against 39 phosphory-
lated receptor tyrosine kinases (Supplementary Fig. S1). Retinal
lysates from P50 rd10 mice on either regular or norgestrel-
supplemented diets were prepared using the lysis buffer
supplied with the kit along with protease and phosphatase
inhibitors (Thermo Fisher Scientific). Protein concentration
was measured using a Bradford assay (Bio-Rad). Lysates from
three mice per group were pooled to a total of 140 lg. Hence,
140 lg protein was used per membrane and two membranes
were used in total (untreated and norgestrel). The array
procedure was carried out per manufacturer instructions.
Membranes were exposed to X-ray film for 10 minutes.
Electroretinograph Recordings
Scotopic electroretinograms (ERG) were performed at P50, P60,
and P80 in overnight dark-adapted (12 hours) animals. Animals
were prepared for bilateral ERG recording under a dim red light.
Mice were anesthetized by an intraperitoneal injection of
ketamine (100 mg/kg) and xylazine (4 mg/kg), and kept on a
thermal blanket at 388C. Pupils were dilated by topical
application of 1% tropicamide (Alcon Cus´ı, Barcelona, Spain),
and 0.2% polyacrylic acid carbomer viscotears (Novartis,
Barcelona, Spain) was instilled on the corneas to prevent
dehydration and allow electrical contact with the recording
electrodes consisting of DTL fiber with an X-Static silver-coated
nylon conductive strand (Sauquoit Industries, Scranton, PA,
USA). A platinum 25-gauge needle was inserted under the scalp
between the eyes as a reference electrode and a gold electrode
was placed in the mouth as ground. All the experiments were
performed in total darkness in a Faraday cage to avoid external
electrical interference. Scotopic ERG responses, in both eyes,
were induced by flash light stimuli produced with a Ganzfeld
illuminator. Eleven increasing luminances, ranging from5 to 1
log cd s/m2, of 10-ms duration were presented to the animals at
intervals of 10 seconds for dim flashes (5 to0.6 log cd s/m2)
and 20 seconds for the highest flashes (0–1 log cd s/m2). ERG
responses were amplified and band-filtered (1–1000 Hz, without
notch filtering) using a DAM50 data acquisition board (World
Precision Instruments, Aston, UK). Stimuli presentation and data
acquisition at 4 kHz were performed using a PowerLab system
(ADInstruments, Oxford, UK). The amplitude of the a-wave was
measured from the baseline to the most negative trough, while
the amplitude of the b-wave was measured from the trough of
the a-wave to the peak of the b-wave.
Optomotor Testing of Visual Acuity
Visual acuity (VA) evaluation by optomotor testing, related to
cone photoreceptor function,32,33 was assessed at P50, P60,
and P80. The assessment of VA was performed using an Argos
optomotor system (Instead Technologies, Elche, Spain). The
Argos system consists of a chamber created from four
computer monitors facing each other forming a square. A
charge-coupled device camera with an infrared light lamp in
the upper part of the system records the animals placed on a
platform in the center of the cube. Mice were allowed to move
freely on the platform. The stimuli consisting of black and
white bars rotating around the animal were projected in the
monitors and were displayed with a frequency of 0.088 cycles/
degree for 5 seconds and 100% contrast. The experimenter
decided whether the mice performed the tracking motions
consisting of a reflexive neck and head movement in the
direction of the rotating vertical gratings. The maximum VA
corresponded to the spatial frequency threshold obtained by
increasing systematically the spatial frequency until the mouse
no longer responded.
Retinal Explant Culture
Retinal explants were prepared from P14 wild-type and P30
rd10 mice. Eyes were enucleated and transferred to a sterile
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laminar flow hood. Whole retinas were carefully dissected and
placed photoreceptor-side down on a cell culture insert in
advanced Dulbecco’s modified Eagle’s medium (DMEM)-F12
(Sigma-Aldrich Corp.) supplemented with 1% penicillin/strep-
tomycin. Retinal explants were cultured for 48 hours in six-
well plates with 1.5 mL media per well/explant. Explants were
exposed to various concentrations of trametinib (10 mM stock
in dimethyl sulfoxide [DMSO]) (ApexBio, Houston, TX, USA)
ranging from 10 to 200 nM. All explants were exposed to the
same volume of DMSO. The vehicle control was exposed to
DMSO alone.
Experimental Design and Statistical Analysis
The number of animals (N) and/or eyes (n) used for each
experimental analysis is detailed in Supplementary Table S2,
along with the type of test used and statistical results. Values in
all graphs represent the mean 6 standard error of the mean
(SEM). Data were statistically analyzed using either unpaired 2-
tailed Student’s t-test or 1-way ANOVA with Dunnett’s/Tukey’s
multiple comparisons (GraphPad, Prism 6; San Diego, CA, USA)
with values of P  0.05 being considered statistically
significant. For ERG and optomotor tests, a 2-way ANOVA
(Statistical Package for Social Sciences, Chicago, IL, USA) was
used to analyze the functional differences between the groups
at different ages (P50, P60, and P80). Post hoc pairwise
comparisons using Bonferroni’s test were carried out when P
 0.05. Normal distributions and homogeneity of variance
were seen for the categories of the previously defined
variables.
RESULTS
The Course of Cone Cell Degeneration in the rd10
Retina
In the rd10 retina, rod cell death begins ~P15, and by P25
almost all of the rod photoreceptors have been lost.26 Changes
in cone cell morphology, as visualized by cone arrestin, take
place between P20 and P60 (Fig. 1A(i), cone arrestin). Cone
cell degeneration progresses by outer segment collapse and
cell death. By P60, cone arrestin is sparse in the rd10 retina and
a defined outer nuclear layer (ONL) no longer exists (Fig.
1A(i)). Concomitant with the degeneration of cone cells,
synaptic connectivity, as assessed by levels of synaptophysin, is
lost in the outer plexiform layer (Fig. 1A(i), synaptophysin).
Quantification of fluorescence intensity revealed significant
reductions in both cone arrestin and synaptophysin between
P20 and P60 in the rd10 retina (Fig. 1A(ii)).
Norgestrel Administration in the Mid-Late Stages of
RP Preserves Cone Cells
We administered a norgestrel-supplemented diet to rd10 mice
at P30 (Fig. 2A), when rod cells have almost been completely
lost26 and cone cell degeneration has begun (Fig. 1).
Assessment of cone cell morphology in retinal sections 20
days later at P50 revealed substantial preservation of cone cells
(cone arrestin) as well as synaptic connectivity in the outer
plexiform layer (synaptophysin) in norgestrel-fed rd10 mice
compared to untreated (Fig. 2B(i)). Measurement of fluores-
FIGURE 1. The course of cone cell degeneration in the rd10 retina. (A) (i) Cone cell morphology (cone arrestin; green) and synaptic connectivity in the
outer plexiform layer (synaptophysin; magenta) decreased in retinal sections from rd10 mice between P20 and P60. Nuclear staining (Hoechst; blue) is
shown for a small portion of each image to highlight individual cell layers. (A) (ii) Quantification of immunofluorescence intensity reveals significant
reductions in both cone arrestin and synaptophysin between P25 and P60 compared to P20, in the rd10 retina (1-way ANOVA with Dunnett’s multiple
comparisons). Data are presented as mean 6 SEM; *P  0.05, **P  0.01, ***P  0.001; see Supplementary Table S2. INL, inner nuclear layer.
Neuroprotection of Cone Photoreceptors With Norgestrel IOVS j July 2019 j Vol. 60 j No. 8 j 3224
Downloaded from iovs.arvojournals.org on 07/29/2019
FIGURE 2. Norgestrel administration from P30 preserves cone cells and synaptic connectivity. (A) Diet supplementation with norgestrel
commenced from P30 in the rd10 mouse, when the majority of rod cells have been lost and cone cell degeneration is beginning. (B) (i) Visualization
of cone arrestin and synaptophysin at P50 in the rd10 retina revealed a norgestrel-mediated preservation of both cone cells and synaptic
connectivity in the outer plexiform layer. Wild-type retina is shown for comparison. (B) (ii) Measurement of immunofluorescence intensity
confirmed significant increases in cone arrestin and synaptophysin in the norgestrel-treated mice at P50 compared to untreated rd10. Quantification
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cence intensity at P50 revealed significant reductions in both
cone arrestin and synaptophysin in untreated rd10 retinas
compared to wild type, and significant preservation of cones
and synapses in the rd10 retina following norgestrel adminis-
tration (Fig. 2B(ii)). As expected due to the widespread loss of
rod photoreceptors, quantification of the number of nuclei in
the ONL demonstrated significantly less cells in the P50 rd10
retina compared to wild type. Norgestrel diet supplementation
resulted in the presence of significantly more cells in the rd10
ONL compared to untreated (Fig. 2B(ii)).
To gain a greater understanding of the level of neuropro-
tection offered by norgestrel, we used whole-mount samples to
visualize the entire retinal landscape of cone cell morphology.
We harvested retinas from P50, P60, and P80 rd10 mice for this
analysis and used an antibody against cone arrestin. In the
untreated retinas at all ages, cone arrestin-positive cells were
sparse (Fig. 2C(i), rd10). In stark contrast, norgestrel-fed mice
had far higher densities of cone arrestin-positive cells at all ages
(Fig. 2C(i), rd10 norgestrel). Quantification confirmed signifi-
cantly more cone arrestin-positive cells in the retinas of
norgestrel-fed mice at P50, P60, and P80 compared to age-
matched untreated (Fig. 2D). Incredibly, up to 28-fold more
cone arrestin-positive cells were present following norgestrel
treatment (Fig. 2D). Interestingly, this level of cell density in
the norgestrel-fed mice at P50 was similar to that in untreated
mice at P30 (Fig. 2D), suggesting that little or no degeneration
of cone cells occurred once norgestrel administration com-
menced. In fact, number of cone cells in the norgestrel-fed
rd10 mice at P50 was comparable to that of the wild type at
P50 (Fig. 2D). As norgestrel treatment resulted in 70% greater
numbers of nuclei in the ONL (Fig. 2B(ii)) compared to 770%
greater numbers of cone arrestin-positive cells (Fig. 2D) at P50,
this indicates that norgestrel’s predominant neuroprotective
effect is through the preservation of cone cell morphology
rather than overall numbers of cone cells. Therefore, norgestrel
administration in the mid-late stages of RP immediately halted
cone cell degeneration and preserved cone cell morphology
for at least a further 50 days, despite the previous widespread
loss of rod photoreceptors.
Norgestrel Preserves Retinal Function
Despite similar densities, a noticeable difference in the
morphology of cone cells was observed between wild-type
and norgestrel-fed mice at P50 (Figs. 2C(i), white boxes;
2C(ii)). Wild-type cone cells appeared hair-like whereas those
in the norgestrel-fed rd10 mice were round (Figs. 2C(i), 2C(ii)).
This difference in morphology is not surprising considering the
widespread absence of rod photoreceptors and thus structural
deficits in the norgestrel-treated retinas from P30.14 Thus, we
sought to determine if the preserved cone cells functioned
normally in the norgestrel-fed rd10 mice. Retinal function was
assessed in vivo in untreated and norgestrel-fed rd10 mice
using ERG recordings and optomotor testing at P50, P60, and
P80. ERGs revealed significant preservation of retinal function
at P50, P60, and P80 in both a-wave (photoreceptor response)
and b-wave amplitudes (response of the inner retina). Wild-
type responses at P50 are shown for comparison (Fig. 3A(i)).
Example ERG traces depict stronger responses with norgestrel
at all ages compared to untreated rd10 mice (Fig. 3A(ii)). Cone
cells are responsible for high-level VA, which can be robustly
measured using the optomotor test.32,33 Investigation of retinal
function in awake mice using optomotor testing confirmed a
significantly higher level of VA in norgestrel-fed mice at P50,
P60, and P80 (Fig. 3B). In fact, VA in the norgestrel-treated rd10
mice at P50 was 40% that of the wild-type level. Thus,
norgestrel-mediated protection of cone cells importantly
transpired to a significant preservation of retinal function.
Rod Photoreceptors Are Sparse in the Norgestrel-
Treated Mice
We wished to delineate the mechanism(s) driving norgestrel-
mediated protection of cone cells in the rd10 retina. As
discussed in the introduction, cone cells rely heavily on rod
cells for trophic support and so we felt it necessary to consider
the possible role of norgestrel-mediated protection of remain-
ing rod cells in promoting cone cell protection. As shown in
Figure 4, sparse staining of rhodopsin was evident in whole-
mount retinas from untreated P50 and P80 rd10 mice in
contrast to the strong, dense immunoreactivity observed in the
wild-type retina at P50. Rhodopsin immunoreactivity was
slightly higher in the norgestrel-treated retinas at P50 and P80
compared to untreated, suggesting marginal protection of the
few remaining rod cells (Fig. 4)—albeit, it was clear that rod
cell death was widespread in both untreated and norgestrel-
treated retinas and that there was a progression of rod cell loss
between P50 and P80 with norgestrel. Taking this together
with the significant preservation of cone cell morphology and
function out to P80, we propose that norgestrel-driven
protection of cone cells is unlikely to be solely due to
preservation of rod-derived trophic support.
Norgestrel Does Not Alter Microglial/Macroglial
Inflammatory Processes
We have previously demonstrated that norgestrel promotes
photoreceptor survival in the early stages of disease by
dampening harmful microglial/macroglial processes.26,28,34
Inflammation might be playing a role in cone cell
death9–11,30,35 and so we studied microglia/macrophage
dynamics. Visualization of Iba1þ cells in retinal sections at
P50 revealed similar microglia/macrophage numbers, localiza-
tion, morphology, and phagocytic state (CD68) between
untreated and norgestrel-treated mice (Fig. 5A). Analysis of
microglia/macrophage number and phagocytic state in z-stacks
of whole-mount retinas, inclusive of all layers, supported this
result (Fig. 5B(i)) and confirmed similar numbers of microglia/
macrophages (Iba1þ cells) and percentages of CD68þ microg-
lia/macrophages between groups (Fig. 5B(ii)). Close to 100% of
Iba1þ cells were positive for CD68 in both groups, indicating
extensive phagocytic states.
of the number of nuclei in the ONL confirmed significantly less cells in the rd10 retina compared to wild type (1-way ANOVA with Tukey’s multiple
comparisons). There were significantly more cells in the ONL of rd10 retinas treated with norgestrel compared to untreated (unpaired Student’s t-
test). This difference was not significant with an ANOVA due to the presence of rods in the wild-type retina, accounting for 95% of photoreceptors.
(C) (i) Whole-mount retinas from P50, P60, and P80 untreated rd10 mice reveal sparse cone arrestin-positive cells (white) whereas rd10 mice on a
norgestrel-supplemented diet reveal dense populations at all ages. Whole-mount retina from wild-type P50 is shown for comparison. (C) (ii) Higher-
magnification images (white boxes in C[i]) depict differences in cone cell morphology between norgestrel-treated rd10 mice and wild type. (D)
Quantification of the number of arrestin-positive cells per 0.016 mm2 confirms significantly more cone cells present in the norgestrel-treated rd10
mice compared to age-matched untreated rd10. There was no significant difference between the wild-type and norgestrel-treated rd10 mice at P50
or between the P30 untreated rd10 and P50 norgestrel-treated rd10 (unpaired Student’s t-test). Data are presented as mean 6 SEM; *P  0.05, **P 
0.01, ***P  0.001, ****P  0.0001; see Supplementary Table S2.
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Our previous work on macroglial activity in the diseased
retina has shown that norgestrel significantly reduces Mu¨ller
cell gliosis,34 a process believed to impede tissue repair and
remodeling following injury.36,37 We therefore investigated the
possibility that norgestrel was using this mechanism to protect
cone cells. Assessment of Mu¨ller cell gliosis by glial fibrillary
acidic protein (GFAP) immunoreactivity in retinal sections, a
well-characterized marker of gliosis,36,37 alongside glutamine
synthetase (a Mu¨ller cell–specific protein) revealed similar
levels between untreated and norgestrel-treated mice at P50
(Fig. 6A(i)). GFAP is also expressed by astrocytes in the retina,
which reside in the retinal ganglion cell layer. Z-stacks of GFAP
immunoreactivity in whole-mount retinas presented a typical
stellate astrocytic morphology, with similar levels of GFAP
throughout the retina (Fig. 6A(ii)). Western blot analysis for
GFAP and glutamine synthetase levels confirmed that gliosis is
unaffected by norgestrel treatment (Fig. 6B). Taken together
with the data in Figure 5, these results suggest that norgestrel is
not targeting either microglia/macrophage or macroglia
inflammatory processes to promote preservation of cone cells.
Norgestrel Does Not Affect Oxidative Stress
As oxidative stress is a major contributing factor to cone cell
loss in RP,5–7,38,39 and norgestrel is known to alleviate oxidative
stress in a light-damage model of retinal degeneration via
upregulation of antioxidant enzymes,25 we investigated anti-
oxidative mechanisms as a possible neuroprotective strategy
FIGURE 3. Norgestrel preserves retinal function. (A) (i) Light intensity response curves of P50, P60, and P80 rd10 mice untreated (black boxes) or
on norgestrel-supplemented diets (gray circles). Wild-type responses at P50 are shown for comparison (black triangles). Statistically significant
increases were observed in rd10 retinas with norgestrel, in both a-wave and b-wave amplitudes at all ages, compared to untreated (2-way ANOVA
with Bonferroni’s pairwise comparisons). (A) (ii) Representative ERG waveforms performed on untreated rd10 and norgestrel-fed rd10 mice at P50,
P60, and P80 indicating increased neurotransmission in the rd10 retina with norgestrel. An ERG trace from a wild-type adult is shown for
comparison. (B) Visual acuity measured by the optomotor test revealed significant increases with norgestrel at P50, P60, and P80 compared to
untreated rd10 (unpaired Student’s t-test). Wild-type visual acuity is shown at P50 for comparison. Data are presented as mean 6 SEM; **P  0.01,
***P  0.001; see Supplementary Table S2 for details.
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against cone cell degeneration. First, we assessed levels of
acrolein, a reactive aldehyde and marker of oxidative stress in
the diseased retina. Acrolein immunoreactivity was strongest in
the outer retina in both untreated and norgestrel-treated mice
at P50 and similar levels were observed between groups (Fig.
7A), suggesting that norgestrel does not reduce oxidative stress
to combat cone cell degeneration. In line with this, we did not
see any increase in the antioxidative enzymes SOD1, SOD2,
catalase, glutathione reductase, and glutathione peroxidase
with norgestrel (Fig. 7B). In fact, we found significant
decreases in levels of SOD1 and SOD2 with norgestrel (Fig.
7B(ii)).
Oxidative stress can promote mitochondrial damage and
subsequent apoptosis.37,40,41 Bcl-2 is an antiapoptotic protein
located at the mitochondrial outer membrane and works by
inhibiting the proapoptotic protein Bax. Mitochondrial-in-
duced apoptosis occurs via activation of caspases 3 and
9.40,41 Bax-mediated cell death has been demonstrated in
models of RP,42 and progestins are known to increase mRNA
levels of Bcl-2 via interaction of the progesterone receptor to
the Bcl-2 promoter.43 We therefore investigated the possibility
that norgestrel was preventing the damaging effects of
oxidative stress at the level of Bcl-2. This was shown not to
be the case, as Western blot analysis revealed similar levels of
Bcl-2 and its target Bax between groups at P50, along with
caspase 3 and caspase 9 (Fig. 7C).
Norgestrel Stimulates ERK1/2 Signaling in Mu¨ller
Glial Cells
Our group has published several studies highlighting a
norgestrel-mediated upregulation of growth factors that
promotes photoreceptor survival.27,44–46 Growth factors me-
diate their effects via binding to receptor tyrosine kinases.47
We therefore turned our attention to growth factor signaling as
a mechanism for norgestrel-driven protection of cone cells in
FIGURE 4. Rod cells are sparse in the norgestrel-treated rd10 retinas. Rhodopsin staining in whole-mount untreated rd10 retina is sparse at P50 and
absent at P80, as demonstrated by both low- and high-magnification images. Wild-type P50 retinas are shown for comparison and show intense and
dense rhodopsin staining. Rhodopsin staining is also sparse in the norgestrel-treated mice at P50 and P80 although some cell bodies can be
observed. The optic nerve head (ONH) is shown by a dotted circle. Scale bars represent 300 and 30 lm.
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the rd10 retina. To study this thoroughly, we used a
phosphoreceptor tyrosine kinase array in which antibodies
for 39 receptor tyrosine kinases are represented on a single
membrane (see Methods for full details and Supplementary Fig.
S1). This revealed an interesting result in that the receptor with
the highest level of activation in both untreated and norgestrel-
treated P50 retinas was ErbB2 (analogous with human ERBB2/
HER2) (Supplementary Fig. S1). More interesting still, norges-
trel-treated retinas had a ~100% increase in ErbB2 activity
compared to untreated (Fig. 8A). ErbB2 is a member of the
epidermal growth factor (EGF) family of receptors. Activation
of ErbB2 leads to downstream activation of Akt and extracel-
lular signal-related kinase 1 and 2 (ERK1/2), pathways involved
in cell survival and proliferation. Western blot analysis of pAkt
and its downstream target mammalian target of rapamycin
(mTOR) did not show any change with norgestrel (Figs. 8B(i),
8B(ii)). However, both pERK1 and pERK2 were significantly
increased with norgestrel (Figs. 8B(i), 8B(ii)). An increase in
pMEK1/2, an upstream regulator of pERK1/2, was also
observed (Figs. 8B(i), 8B(ii)).
Using whole-mount retinas from P50 mice, a norgestrel-
dependent increase in pERK1/2 was confirmed by immuno-
fluorescence with clear cluster-like areas of strong immunore-
activity (Fig. 8C(i)). In order to determine the cellular location
of pERK1/2, pERK1/2 was first visualized alongside cone
arrestin in norgestrel-treated retinas. It was clear that pERK1/2
did not colocalize with cone arrestin and instead depicted a
Mu¨ller glial cell morphology (Fig. 8C(ii)). To confirm this,
pERK1/2 was visualized alongside GFAP, and indeed there was
some level of colocalization (Fig. 8C(ii)). Hence, treatment
with norgestrel resulted in an upregulation of ErbB2 activity in
the rd10 retina, a receptor tyrosine kinase strongly implicated
in cell proliferation, differentiation, and survival. An increase in
ERK1/2 signaling, a well-studied consequence of ErbB2
activation, was observed in Mu¨ller glia.
ERK1/2 Signaling Is Critical for Norgestrel-
Mediated Neuroprotection of Cone Cells
We hypothesized that ERK1/2 signaling was playing a crucial
role in norgestrel-mediated neuroprotection of cone photore-
ceptors in the rd10 retina. To investigate this, we wished to
administer norgestrel in combination with an inhibitor of
ERK1/2 signaling. Trametinib is a MEK1/2 inhibitor, which
consequently prevents phosphorylation and thereby activity of
ERK1/2.48–51 Using retinal explants from wild-type mice, we
administered various concentrations of trametinib (10, 50, 100,
and 200 nM) over 48 hours and found that all concentrations
resulted in significant decreases in levels of pERK1/2
compared to vehicle, whereas total ERK1/2 remained un-
changed, as assessed by Western blot (Fig. 9A). The lowest
levels of pERK1/2 were observed with 100 nM trametinib (Fig.
FIGURE 5. Norgestrel does not affect microglia/macrophage numbers, morphology, or phagocytic states. (A) Visualization of microglia/macrophages
(Iba1; magenta) alongside a marker of phagocytosis (CD68; green) reveals similar numbers, morphology, localization, and phagocytic states in retinal
sections from untreated and norgestrel-treated mice at P50. Nuclear staining (Hoechst; blue) is shown for a small portion of each image to highlight
individual cell layers. (B) (i) Whole-mount retinas from P50 mice, inclusive of all retinal layers, reveal similar numbers, morphology, and phagocytic
states of Iba1þcells between untreated and norgestrel. (B) (ii) Quantification of Iba1þcells and CD68þcells confirms no significant difference between
groups (unpaired Student’s t-test). Data are presented as mean 6 SEM; see Supplementary Table S2 for details. RGC, retinal ganglion cells.
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9A(ii)). To ascertain the role of ERK1/2 signaling in norgestrel-
mediated neuroprotection of cone cells in the rd10 retina,
retinal explants were prepared from P30 rd10 mice and treated
with either vehicle, norgestrel, or norgestrelþ trametinib over
48 hours. Norgestrel-treated retinas retained significantly
higher numbers of arrestin-positive cells compared to vehicle,
as visualized and quantified in whole-mount preparations (Fig.
9B). Treatment of rd10 retinal explants with norgestrel in the
presence of trametinib prevented this neuroprotective effect
(Fig. 9B). Quantification of arrestin-positive cells confirmed a
critical role for ERK1/2 signaling in norgestrel-driven neuro-
protection of cone cells (Fig. 9B(ii)).
DISCUSSION
This study was designed to investigate the long-term neuro-
protective potential of norgestrel, a synthetic progestin, when
administered in the mid-late stages of RP when the majority of
rod cells have already been lost and cone cell degeneration is
beginning. Investigations of therapeutic interventions that are
effective at this stage of the disease are critical, considering
that rod cell death can go unnoticed for some time along with
the debilitating effects of cone cell loss on daytime vision. In
the rd10 retina at P30, rod cell death is almost complete and
cone degeneration has begun14 (Figs. 1, 2). As rod cells
FIGURE 6. Norgestrel does not alter levels of GFAP. (A) (i) Assessment of Mu¨ller cell morphology (glutamine synthetase [GS]; green) and gliosis
(GFAP; magenta) in retinal sections from P50 untreated and norgestrel-treated mice showed similar results. Nuclear staining (Hoechst; blue) is
shown for a small portion of each image to highlight individual cell layers. (A) (ii) Whole-mount retinal analysis of GFAP at P50, inclusive of all retinal
layers, revealed similar levels and morphology of GFAP immunoreactivity. Astrocytes can be observed by their typical stellate appearance. (B) (i)
Western blot analysis supported immunofluorescent findings and (B) (ii) confirmed similar levels of GFAP and glutamine synthetase (GS) between
untreated and norgestrel-treated mice at P50 (unpaired Student’s t-test). REVERT Total Protein Stain demonstrates equal loading of samples. Data are
presented as mean 6 SEM; see Supplementary Table S2 for details. RGC, retinal ganglion cells.
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account for at least 95% of photoreceptors,3,52 the P30 retina
has undergone considerable cell death and widespread
structural alterations.
Administration of a norgestrel-supplemented diet to rd10
mice from P30 resulted in profound neuroprotection of
existing cone cells in the following 50 days, with the number
of cone arrestin-positive cells almost 13-fold higher than in
untreated at P80 (Fig. 2D). As norgestrel treatment resulted in
70% greater numbers of nuclei in the ONL (Fig. 2B) compared
to 770% greater numbers of cone arrestin-positive cells (Fig.
2D) at P50, we propose that norgestrel predominantly protects
cone cell morphology. A similar effect has been previously
reported following administration of ciliary neurotrophic
factor (CNTF) in a rat model of RP.53 Critically, this protection
of cone cells transpired to a significant preservation of retinal
function as measured by ERG recordings and optomotor
testing (Fig. 3). Interestingly, although P50 wild-type ERG
responses are far higher compared to rd10 treated with
norgestrel, measures of VA in awake mice were much closer
between the two groups, indicating a high degree of vision
overall (Fig. 3). Hence, norgestrel could potentially be used in
both the early26 and mid-late stages (current study) of the
disease. Critically, it could provide long-term protection of
cone cells and preservation of color/daytime vision.
Previous work has demonstrated the ability of norgestrel to
promote photoreceptor survival and preserve retinal function
when administered prior to photoreceptor loss in the rd10
mouse.26 Our work has shown that norgestrel orchestrates a
strong neuroprotective defense against the underlying disease
by utilizing multiple signaling pathways and targeting several
cell types. Norgestrel dampens harmful microglia/macrophage
activity, gliosis, and oxidative stress in the early stages of the
disease.25,26,28,34 Surprisingly, although high levels of microg-
lial/macrophage activity, gliosis, and oxidative stress were
observed in the rd10 retina during cone cell degeneration,
norgestrel administration did not reduce any of these effects
(Figs. 5–7). We propose that such processes are more strongly
associated with rod cell death and its aftermath, and are not the
predominant driving forces of cone cell degeneration in RP, as
norgestrel promoted remarkable protection of cones despite
prevailing inflammation and oxidative stress. In fact, we
observed significant reductions in levels of the antioxidant
enzymes SOD1 and SOD2 in the norgestrel-treated mice (Fig.
7). This could be due to a healthier retina requiring less
FIGURE 7. Norgestrel does not alter levels of oxidative stress. (A) (i) Acrolein was visualized as a marker of oxidative stress and was observed in the
outer retina, at similar levels in untreated and norgestrel-treated mice at P50. (A) (ii) Measurement of immunofluorescence intensity confirmed
similar levels of acrolein between groups (unpaired Student’s t-test). (B) (i) Western blot analysis for antioxidant enzymes demonstrated similar
levels of catalase, glutathione reductase, and glutathione peroxidase between untreated and norgestrel-treated retinas at P50. SOD1 and SOD2 levels
were lower with norgestrel. REVERT Total Protein Stain demonstrates equal loading of samples. (B) (ii) Densitometry analysis confirmed norgestrel-
driven decreases in SOD1 and SOD2 and similar levels of catalase, glutathione reductase, and glutathione peroxidase between groups (unpaired
Student’s t-test). (C) (i) Western blot analysis for Bcl-2, Bax, caspase 3, and caspase 9 demonstrated similar levels between untreated and norgestrel-
treated retinas at P50. REVERT Total Protein Stain demonstrates equal loading of samples. (C) (ii) Densitometry analysis confirmed similar levels of
Bcl-2, Bax, caspase 3, and caspase 9 between groups (unpaired Student’s t-test). Data are presented as mean 6 SEM; *P  0.05; see Supplementary
Table S2 for details.
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FIGURE 8. Norgestrel administration results in increased activation of ErbB2 and ERK1/2. (A) Using a receptor-tyrosine kinase activity array,
significantly increased levels of activated ErbB2 were found in retinas from norgestrel-treated rd10 mice compared to untreated at P50. (B) (i)
Assessment of components of the Akt and ERK1/2 pathways by Western blot at P50 demonstrates unchanged activity of the Akt pathway (pAkt, Akt,
pmTOR, and mTOR) whereas clear increases in levels of pERK1/2 and pMEK1/2 are seen. REVERT Total Protein Stain demonstrates equal loading of
samples. (B) (ii) Densitometry analysis confirms significant increases in pERK1 and pERK2 following norgestrel treatment (unpaired Student’s t-
test). (C) (i) An increase in pERK1/2 with norgestrel was observed in whole-mount retinas and appeared in clusters. (C) (ii) Investigations on the
cellular location of pERK1/2 revealed an absence of pERK1/2 in cone photoreceptors (pERK1/2 and cone arrestin) and a high level of colocalization
in Mu¨ller glia (pERK1/2 and GFAP). Nuclear staining (Hoechst; blue) is shown for a small portion of each image to highlight individual cell layers.
Data are presented as mean 6 SEM; *P  0.05, **P  0.01; see Supplementary Table S2 for details.
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antioxidant defenses. Although there is some evidence for
mitochondrial damage and subsequent activation of apoptotic
pathways in animal models of RP,42 this was observed in the
early stages of the disease, prior to or during rod cell death.
Hence, it is possible that these pathways either are not
implicated or are not the dominant driving force behind cone
cell loss (Fig. 7). In addition, we conclude that norgestrel is not
mediating its effects via insulin/mTOR signaling, a pathway
implicated in cone cell death and survival in RP.8 We did not
detect any activation of insulin receptors in either the
untreated or norgestrel-treated retinas (Supplementary Fig.
S1). In line with this, we did not observe any change in the
activation of mTOR (Fig. 8B).
Our studies on the possible role of growth factor signaling
in norgestrel-mediated neuroprotection presented a new and
exciting result. ErbB2 receptor activity was significantly
upregulated with norgestrel (Fig. 8). ErbB2 (analogous with
human ERBB2/HER2) belongs to the family of EGF receptors
and has been widely studied in the field of cancer research.54
Elevated ErbB2 activity is a hallmark of many cases of breast
cancer and has been shown to drive signaling pathways for cell
survival, differentiation, and proliferation.54 Progestins have
previously been shown to increase EGF receptor activity and
its downstream pathways in breast cancer cells.55,56 This could
be due to the autocrine actions of progesterone receptors as
transcription factors for EGF receptors and their ligands.55,57
A major signaling pathway driven by activation of ErbB2 is
the MAP-kinase or ERK1/2 pathway, which has been demon-
strated to drive differentiation and proliferation.54 It was
interesting to see an increase in ERK1/2 activity in Mu¨ller glia
specifically (Fig. 8C) considering that these cells have the
capacity to dedifferentiate into neuronal cells following retinal
injury and neuronal loss.58 In chick and fish retinas, Mu¨ller glia
undergo dedifferentiation and can successfully replace lost
neurons. In the mammalian retina, however, Mu¨ller glia initiate
the dedifferentiation process but fail to fully function as retinal
progenitors.58 Interestingly, Mu¨ller glia in the mammalian
retina can be encouraged to proliferate and dedifferentiate
with certain molecular cues.59–61 One of the most potent
methods for stimulating Mu¨ller glial proliferation in the
mammalian retina is treatment with EGF, a ligand for the ErbB
family of receptors.59,60,62 When ERK1/2 activity was inhibited
in mouse retinal explants, EGF could no longer stimulate
Mu¨ller glial proliferation.60 EGF-ERK1/2 signaling is known to
occur as part of Mu¨ller glial proliferation and dedifferentiation
in fish retina also.63 Through the inhibition of ERK1/2 ex vivo,
we demonstrated that ERK1/2 signaling is critical for norges-
trel-mediated preservation of cone cells in the rd10 retina (Fig.
9). We hope to further explore the role of Mu¨ller glia and
FIGURE 9. ERK1/2 signaling is critical for norgestrel-mediated protection of rd10 cone photoreceptors. (A) (i) Exposing wild-type retinal explants to
increasing doses of trametinib (a MEK inhibitor) for 48 hours, ranging from 10 to 200 nM, resulted in significant decreases in pERK1/2 whereas
levels of total ERK1/2 remained unchanged. REVERT Total Protein Stain demonstrates equal loading of samples. (A) (ii) Densitometry analysis
confirmed significant trametinib-driven decreases in both pERK1 and pERK2 at all doses (1-way ANOVA with Dunnett’s multiple comparisons). (B)
(i) Whole-mount retinal explants from P30 rd10 mice cultured for 48 hours reveal sparse cone arrestin staining (white) in vehicle treated whereas
norgestrel treatment protected cone photoreceptors. Administration of norgestrel in combination with trametinib attenuated norgestrel’s protective
effects. (B) (ii) Quantification of the number of arrestin-positive cells per 0.021 mm2 confirms significantly more cone cells present in the norgestrel-
treated rd10 mice compared to untreated. There was a significant reduction in the number of arrestinþ cells when norgestrel was administered in
combination with trametinib (1-way ANOVA with Tukey’s multiple comparisons). Data are presented as mean 6 SEM; *P  0.05, ***P  0.001, ****P
 0.0001; see Supplementary Table S2 for details.
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ERK1/2 signaling in norgestrel-driven preservation of cone
cells in the near future.
Taken as a whole, this study presents a promising treatment
for RP in the form of norgestrel, a synthetic progestin.
Norgestrel can protect existing cone photoreceptors and
retinal function for at least 50 days in the rd10 mouse even if
administered in the mid-late stages of the disease, when rod
cells have almost been completely lost and cone cell
degeneration has begun. Thus, norgestrel could potentially
be used to prevent cone cell degeneration and maintain color
vision for those living with RP.
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